The predictive ability of serum α-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance

Journal of Surgical Oncology

Volumn 95, Issue 8, 2007, Pages 645-651

  Huo, Teh Ia ^a,b   Hsia, Cheng Yuan ^a,b   Chu, Chi Jen ^a,b   Huang, Yi Hsiang ^a,b   Lui, Wing Yiu ^a,b   Wu, Jaw Ching ^a,b   Lee, Pui Ching ^b   Chi, Chin Wen ^a,b   Lee, Shou Dong ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

fetoprotein; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Liver cirrhosis; Tumor marker

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; ALPHA-FETOPROTEINS; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34250708343     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20653     Document Type: Article

References (35)

1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
2. Hussain SA, Ferry DR, El-Gazzaz G, et al.: Hepatocellular carcinoma. Ann Oncol 2001;12:161-172.
3. Mita Aoyagi Y, Yanagi M, Suda T, et al.: The usefulness of determining des-gamma carboxyprothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998;82:1643-1648.
4. Nomura F, Ishijima M, Kuwa K, et al.: Serum des-gamma carboxyprothrombin levels determined by a new generation of sensitive immunoassay in patients with smallsized hepatocellular carcinoma. Am J Gastroenterol 1999;94:650-654.
5. Marrero JA, Su GL, Wei W, et al.: Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from non-malignant chronic liver disease in American patients. Hepatology 2003;37:1114-1121.
6. Yoshida S, Kurokohci K, Arima K, et al.: Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 2002;20:305-309.
7. Wang SS, Lu RH, Lee FY, et al.: Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol 1996;25:166-171.
8. Taketa K, Endo Y, Sekiya C, et al.: A collaborative study for the evaluation of lectin-reactive alpha-fetoprotein in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-5423.
9. Tsai JF, Jeng JE, Chuang LY, et al.: Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. Scand J Gastroenterol 2005;40:68-75
10. Sedlaczek N, Hasilik A, Neuhaus P, et al.: Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer 2003;88:733-739.
11. Izzo F, Cremona F, Delrio P, et al.: Soluble interleukin-2 receptor levels in hepatocellular cancer: A more sensitive marker than alfa fetoprotein. Ann Surg Oncol 1999;6:178-185.
12. Marrero JA, Romano PR, Nikolaeva O, et al.: GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005;28:1007-1012.
13. Marrero JA, Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology 2004;127:S113-119.
14. Tu DG, Wang ST, Chang TT, et al.: The value of serum tissue polypeptide specific antigen in the diagnosis of hepatocellular carcinoma. Cancer 1999;85:1039-1043.
15. Trevisani F, D'Intino PE, Morselli-Labate AM, et al.: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-575.
16. Montalto G, Iovanna JL, Soresi M, et al.: Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: Comparison with alpha-fetoprotein. Oncology 1998;55:421-425.
17. Tsai JF, Jeng JE, Chuang LY, et al.: Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma. Tumor Biol 2003;24:291-298.
18. Soresi M, Magliarisi C, Campagna P, et al.: Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003;23:1747-1753.
19. Cedrone A, Covino M, Caturelli E, et al.: Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: Does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology 2000;47:1654-1658.
20. Chen JH, Chau GY, Lui WY, et al.: Surgical results in patients with hepatitis B-related hepatocellular carcinoma and positive hepatitis B early antigen. World J Surg 2000;24:383-387.
21. Chao Y, Li CP, Chau GY, et al.: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003;10:355-362.
22. Huo TI, Wu JC, Lin HC, et al.: Evaluation of the increase in model for end-stage liver disease (ΔMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: Risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005;42:826-832.
23. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
24. Sherman M: Alpha-fetoprotein: An obituary. J Hepatol 2001;34:603-605.
25. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
26. Emond JC, Samstein B, Renz JF: A critical evaluation of hepatic resection in cirrhosis: Optimizing patient selection and outcomes. World J Surg 2005;29:124-130.
27. Liaw YF, Tai DI, Chen TJ, et al.: Alpha-fetoprotein changes in the course of chronic hepatitis: Relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986;6:133-137.
28. Di Bisceglie AM, Sterling RK, Chung RT, et al; HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatol 2005;43:434-441.
29. Hu KQ, Kyulo NL, Lim N, et al.: Clinical significance of elevated alpha-fetoprotein in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004;99:860-865.
30. Chen LT, Liu TW, Chao Y, et al.: Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2005;22:217-226.
31. The CLIP investigators. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-845.
32. Shirabe K, Takenaka K, Gion T, et al.: Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997;64:143-146.
33. Urata K, Matsumata T, Kamakura T, et al.: Lipiodolization for unresectable hepatocellular carcinoma: An analysis of 205 patients using univariate and multivariate analysis. J Surg Oncol 1994;56:54-58.
34. Pompili M, Rapaccini GL, Covino M, et al.: Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001;92:126-135.
35. Huo TI, Huang YH, Lui WY, et al.: Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: Analysis of 543 patients in a single center. Oncol Rep 2004;11:543-550.